Kurzporträt
Umsatz nach Geschäftsbereich
USD in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
Novel Oncology Therapies
100,0
%
| 1 | 100,0 % | 1 | 100,0 % | -47.32% |
Umsatz je Region
USD in Millionen | 2022 | Gewichtung | 2023 | Gewichtung | Delta |
---|---|---|---|---|---|
United States
100,0
%
| 1 | 100,0 % | 1 | 100,0 % | -47.32% |
Manager
Manager | Titel | Alter | Seit |
---|---|---|---|
James Breitmeyer
FOU | Founder | 70 | 01.01.97 |
Richard Vincent
DFI | Director of Finance/CFO | 61 | 01.04.17 |
Salim Yazji
CTO | Chief Tech/Sci/R&D Officer | 55 | 17.05.21 |
Rajesh Krishnan
CTO | Chief Tech/Sci/R&D Officer | 51 | 28.08.19 |
Pablo Urbaneja
PRN | Corporate Officer/Principal | - | 01.07.21 |
Anita Wiseth
HRO | Human Resources Officer | - | 01.03.21 |
Chase Leavitt
LAW | General Counsel | 42 | 12.04.21 |
Aufsichtsräte
Aufsichtsräte | Titel | Alter | Seit |
---|---|---|---|
David Hale
FOU | Founder | 75 | 01.01.97 |
Dan Kisner
BRD | Director/Board Member | 77 | 07.06.19 |
Rosemary Mazanet
BRD | Director/Board Member | 67 | 27.01.21 |
James Breitmeyer
FOU | Founder | 70 | 01.01.97 |
William LaRue
BRD | Director/Board Member | 73 | 01.12.17 |
Michael Carter
BRD | Director/Board Member | 86 | 07.06.19 |
Charles Theuer
BRD | Director/Board Member | 60 | 01.05.18 |
Jill DeSimone
BRD | Director/Board Member | 68 | 03.01.23 |
Robert Wills
BRD | Director/Board Member | 70 | 07.06.19 |
Xin Nakanishi
BRD | Director/Board Member | 62 | 01.11.18 |
Anteilsklasse
Vote | Menge | Streubesitz | Konzerneigene Aktien | Total Float | |
---|---|---|---|---|---|
Aktie A | 1 | 2 959 645 | 2 700 684 ( 91,25 %) | 0 | 91,25 % |
Unternehmenskontakt
Sektor
% 1. Jan. | Kap. | |
---|---|---|
+1.14% | 42.86 Mrd. | |
+13.77% | 42.74 Mrd. | |
+45.04% | 41.36 Mrd. | |
-6.20% | 27.68 Mrd. | |
+6.91% | 25.15 Mrd. | |
-23.44% | 18.63 Mrd. | |
+29.83% | 12.37 Mrd. | |
-2.83% | 11.92 Mrd. | |
+7.13% | 11.21 Mrd. |